QuantRx Biomedical Corp. of Doylestown, Pa., has announced that Phase 1 trials have begun for the BFPET blood flow imaging agent for PET. An affiliated company, FluoroPharma Inc. of Boston will evaluate the safety, distribution and dosimetry of the agent for myocardial perfusion imaging in healthy subjects.